

## Advantest (6857)

Raising earnings estimates: Expectations for CPU/CPO demand in addition to GPU/ASIC

We revise our earnings estimates based on recent developments. We maintain our Overweight rating and raise our price target to ¥41,000 (from ¥31,000; by end-December 2026). We lower our assumptions for GPU test times (total test times, including the number of processes), but raise our overall estimates to reflect a revised new/upgrade ratio and conservative assumptions for unit price increases. In addition, increases in SoC tester capacity to meet high demand are ahead of schedule. We expect growth to remain strong (we forecast operating profit CAGR of 28% in FY2025–28), driven by expanding opportunities for CPUs and CPOs as well as GPUs and ASICs.

- Earnings estimates:** We revise our operating profit estimates from ¥737.5 billion to ¥778 billion (+56% YoY) for FY2026 and from ¥871.9 billion to ¥952.7 billion (+23% YoY) for FY2027. We introduce an FY2028 estimate of ¥1,039.3 billion (+9%). We lower our assumption for GPU test times (total test times, including the number of processes), which can fluctuate right up until just before chip shipment, from +70% versus the previous generation to +30%, in line with market expectations. However, we raise our estimates to reflect a revised new/upgrade ratio, an increase in SoC tester unit prices (we change our assumption for blended ASPs associated with changes in system configurations from flat YoY to +5% YoY), and growth in shipments accompanying the capacity expansion. Regarding the new/upgrade ratio, we had factored in a certain percentage of upgrades, as the mainstay V93000 Exa Scale can continue to be used across chip generations. However, during its Jan–Mar results briefing, management noted that test content and chip production volumes continue to increase and that demand for new systems would likely continue for at least the next two to three years.
- Ahead of schedule on capacity expansion:** SoC tester capacity was 3,000 units/year as of March 2025. Previously, management aimed for 5,000 units/year at end-FY2026, 7,500 in the next few years, and 10,000 in a few more years. Capacity increases in anticipation of growth in demand for GPUs, ASICs, CPUs, and other applications are ahead of schedule, including the target of 5,000 units/year by end-FY2026. Management expects to reach 10,000 units/year in late 2028 to 2029.

## Overweight

6857.T, 6857.JP  
Price (16 Jun 26):¥30,340

▲ Price Target (Dec-26):¥41,000  
Prior (Dec-26):¥31,000

### Japan Equity Research

#### Technology - Semiconductor/ Technical Materials

#### Mio Shikanai <sup>AC</sup>

(81-3) 6736 1313  
mio.shikanai@jpmorgan.com

#### Junya Ayada

(81-3) 6736 8631  
junya.ayada@jpmorgan.com  
JPMorgan Securities Japan Co., Ltd.

### Key Changes (FYE Mar)

	Prev	Cur	Δ
Adj. EPS - 27E (¥)	738.07	793.50	7.5%
Adj. EPS - 28E (¥)	873.16	971.72	11.3%

### Style Exposure

Quant Factors	Current %Rank	Hist %Rank (1=Top)			
		6M	1Y	3Y	5Y
Value	92	98	89	94	89
Growth	14	18	16	52	52
Momentum	9	3	41	9	14
Quality	7	29	47	21	21
Low Vol	96	98	94	92	85
ESGQ	100	100	100	100	1

Sources for: Style Exposure – J.P. Morgan Global Markets Strategy; all other tables are company data and J.P. Morgan estimates.

See page 7 for analyst certification and important disclosures, including non-US analyst disclosures.

## Price Performance



	YTD	1m	3m	12m
Abs	54.5%	15.1%	25.7%	225.4%
Rel	37.4%	11.8%	15.1%	181.7%

## Company Data

Shares O/S (mn)	732
52-week range (¥)	32,400-8,528
Market cap (\$ bn)	138.5
Exchange rate	160.34
Free float (%)	98.6%
3M ADV (mn)	9.65
3M ADV (\$ mn)	1,572.5
Volatility (90 Day)	73
Index	TOPIX
BBG ANR (Buy   Hold   Sell)	16 7 0

## Key Metrics (FYE Mar)

¥ in millions	2026/3A	2027/3E	2028/3E	2029/3E
<b>Financial Estimates</b>				
Revenue	1,128,610	1,577,500	1,906,500	2,103,500
EBITDA	524,720	805,700	984,600	1,076,600
EBIT	499,120	778,000	952,700	1,039,300
Net income	375,353	575,700	705,000	769,100
Reported EPS	517.36	793.50	971.72	1,060.07
BBG EPS	460.11	693.50	876.93	-
Cashflow from operations	335,182	498,988	646,486	755,458
FCFF	302,170	455,988	594,486	698,458
<b>Margins and Growth</b>				
Revenue Growth Y/Y (%)	44.7%	39.8%	20.9%	10.3%
EBIT margin	44.2%	49.3%	50.0%	49.4%
EBIT Growth	118.8%	55.9%	22.5%	9.1%
EBITDA margin	46.5%	51.1%	51.6%	51.2%
EBITDA Growth Y/Y (%)	105.6%	53.5%	22.2%	9.3%
Net margin	33.3%	36.5%	37.0%	36.6%
Fully Diluted EPS growth	135.5%	53.4%	22.5%	9.1%
<b>Ratios</b>				
Effective Tax Rate	27.4%	26.0%	26.0%	26.0%
Interest cover	-	-	-	-
Net debt/Equity	NM	NM	NM	NM
Net debt/EBITDA	NM	NM	NM	NM
ROE	57.6%	60.9%	55.8%	46.5%
<b>Valuation</b>				
FCFF yield	1.4%	2.1%	2.7%	3.2%
Dividend yield	0.2%	0.4%	0.5%	0.7%
EV/Revenue	17.4	12.4	10.1	9.0
EV/EBITDA	37.5	24.2	19.6	17.5
P/E	58.6	38.2	31.2	28.6

## Summary Investment Thesis and Valuation


### Investment Thesis

Growth in tester needs in connection with the lengthening of test times due to chip advances is a medium-term tailwind. We also expect a focus on Advantest's close ties with key customers in terms of the increasing performance of semiconductors brought about by generative AI advances. Another key factor is whether visibility on ROE upside can be improved through M&A and other capital allocation.

### Valuation

Our December 2026 price target of ¥41,000 is based on our FY2027 EPS estimate (previously our FY2026 EPS estimate) and a P/E of around 42x (previously 43x), 1 standard deviation above the 10-year historical average of around 29x. We add a premium for Advantest due to our expectations for earnings growth.

## Performance Drivers



Factors	6M Corr	1Y Corr
<b>Market: MSCI Japan</b>	0.69	0.46
<b>Sect: Technology</b>	0.73	0.72
<b>Ind: Semicond &amp; S Equip</b>	0.84	0.87
<b>Macro:</b>		
Japan CPI Nationwide YoY	0.21	0.27
MSCI ACWI ex Japan	0.33	0.20
Japan Generic Govt 10Y Yield	-0.35	-0.19
<b>Quant Styles:</b>		
LowVol	-0.63	-0.65
Growth	0.56	0.56
Value	-0.53	-0.56

Table 1: Earnings forecasts

(mn JPY)	2025/3		2026/3					2027/3					2028/3	2029/3	2027/3	
	FY	Act	1Q	2Q	3Q	4Q	FY	1Q	2Q	3Q	4Q	FY	FY	FY	FY	CoE
			Act	Act	Act	Act	Act	JPMe	JPMe	JPMe	JPMe	JPMe	JPMe	JPMe	JPMe	
Sales	779,707		263,776	262,957	273,804	328,073	1,128,610	350,100	386,700	414,700	426,000	1,577,500	1,906,500	2,103,500		1,420,000
Test System Business	682,819		240,554	237,403	245,108	296,325	1,019,390	325,500	359,600	384,300	392,400	1,461,800	1,783,600	1,972,700		1,297,000
Memory Testers	157,700		33,500	43,900	57,300	36,800	171,500	41,300	49,100	50,100	40,700	181,200	272,700	229,600		201,000
SoC Testers	440,400		191,300	173,700	165,200	237,200	767,400	265,600	286,000	306,400	325,200	1,183,200	1,397,800	1,626,000		999,500
Other Systems	84,700		15,800	19,800	22,600	23,200	80,500	18,600	24,500	27,800	26,500	97,400	113,100	117,100		96,500
Services & Others	96,888		23,222	25,554	28,706	31,748	109,230	24,600	27,100	30,400	33,600	115,700	122,900	130,800		123,000
Operating income	228,161		123,952	108,483	113,571	153,114	499,120	175,400	192,100	197,100	213,700	778,000	952,700	1,039,300		627,500
Semiconductor / Component Test Systems	262,120		126,925	113,631	117,144	161,060	518,760	177,000	193,000	197,000	213,000	780,000	953,000	1,038,000		--
Services, Support & Others	-16,125		2,706	342	1,703	4,007	8,758	3,000	3,500	4,200	4,800	15,500	16,900	18,500		--
(Eliminations/Unallocated)	-14,941		-4,616	-4,436	-4,112	-10,784	-23,948	-4,600	-4,400	-4,100	-4,100	-17,200	-17,200	-17,200		--
Profit before tax	224,774		121,357	109,160	113,832	172,371	516,720	--	--	--	--	778,000	952,700	1,039,300		629,000
Net income	161,177		90,180	79,633	78,713	126,827	375,353	--	--	--	--	575,700	705,000	769,100		465,500
D&A	27,100		6,100	6,300	6,400	6,800	25,600	6,100	6,800	7,100	7,700	27,700	31,900	37,300		29,500
Capex	21,000		6,100	9,400	7,800	1,100	34,300	10,000	17,000	14,000	2,000	43,000	52,000	57,000		45,000
R&D	71,400		17,100	18,300	19,200	23,500	78,100	22,700	26,900	29,100	30,500	109,200	151,000	187,700		100,000
Forex																
USDJPY	153		146	146	152	156	150	155	155	155	155	155	155	155		150

Source: Company reports and J.P. Morgan estimates.

Table 2: Advantest (6857): Key changes

	Sales	YoY	OP	YoY	PBT	YoY	NP	YoY	EPS	P/E
	(JPYm)	(%)	(JPYm)	(%)	(JPYm)	(%)	(JPYm)	(%)	(JPY)	(x)
3/24 A	486,507	-13.2%	81,628	-51.3%	78,170	-54.4%	62,290	-52.2%	84.5	348.4
3/25 A	779,707	60.3%	228,161	179.5%	224,774	187.5%	161,177	158.8%	219.7	134.5
3/26 A	1,128,610	44.7%	499,120	118.8%	516,720	129.9%	375,353	132.9%	517.4	57.1
3/27 CoE	1,420,000	25.8%	627,500	25.7%	629,000	21.7%	465,500	24.0%	641.6	45.9
3/27 J.P. Morgan E	1,577,500	39.8%	778,000	55.9%	778,000	50.6%	575,700	53.4%	793.5	37.1
3/27 J.P. Morgan E (old)	1,506,700	33.5%	737,500	47.8%	734,200	42.1%	536,000	42.8%	738.1	39.9
3/27 Bloomberg consensus	1,484,556	31.5%	686,101	37.5%	682,606	32.1%	508,948	35.6%	693.5	42.4
3/28 J.P. Morgan E	1,906,500	20.9%	952,700	22.5%	952,700	22.5%	705,000	22.5%	971.7	30.3
3/28 J.P. Morgan E (old)	1,743,600	15.7%	871,900	18.2%	868,600	18.3%	634,100	18.3%	873.2	33.7
3/28 Bloomberg consensus	1,786,347	20.3%	853,616	24.4%	854,881	25.2%	632,033	24.2%	876.9	33.5
3/29 J.P. Morgan E	2,103,500	10.3%	1,039,300	9.1%	1,039,300	9.1%	769,100	9.1%	1,060.1	27.8
3/29 Bloomberg consensus	2,013,867	12.7%	955,076	11.9%	959,625	12.3%	710,651	12.4%	992.9	29.6

Source: Company reports, Bloomberg Finance L.P., J.P. Morgan estimates.  
Price as of June 15.

Table 3: Consolidated BS/CF

	2021/3	2022/3	2023/3	2024/3	2025/3	2026/3	2027/3	2028/3	2029/3
	FY	FY	FY	FY	FY	FY	FY	FY	FY
	Act	Act	Act	Act	Act	Act	JPMe	JPMe	JPMe
<b>Summarized BS</b>									
Current assets	279,095	304,945	374,695	420,261	599,753	836,407	1,165,864	1,525,748	1,970,187
Cash and cash equivalents	149,164	116,582	85,537	106,702	262,544	339,966	518,423	747,552	1,118,320
Trade receivables	57,028	82,155	102,152	88,855	113,031	228,731	303,741	368,695	405,291
Inventories	64,340	95,013	169,082	204,389	209,707	231,718	307,708	373,509	410,584
Other	8,563	11,195	17,924	20,315	14,471	35,992	35,992	35,992	35,992
Fixed assets	143,546	189,751	225,529	250,968	254,457	335,409	350,709	370,809	390,509
Tangible fixed assets	41,613	51,392	64,046	78,884	78,602	101,628	116,928	137,028	156,728
Goodwill and intangible assets	54,543	85,307	95,767	98,514	78,365	84,250	84,250	84,250	84,250
Other	47,390	53,052	65,716	73,570	97,490	149,531	149,531	149,531	149,531
Current liabilities	89,811	150,882	174,689	126,277	309,424	330,284	376,872	417,213	439,943
Trade debt	58,558	70,352	89,262	76,863	107,093	142,061	188,649	228,990	251,720
Short-term liabilities	0	18,359	13,357	0	74,952	0	0	0	0
Others	31,253	62,171	72,070	49,414	127,379	188,223	188,223	188,223	188,223
Long-term liabilities	52,461	49,193	56,841	113,774	38,247	45,806	45,806	45,806	45,806
Long-term liabilities	0	12,239	20,000	75,143	3	0	0	0	0
Others	52,461	36,954	36,841	38,631	38,244	45,806	45,806	45,806	45,806
Net assets	280,369	294,621	368,694	431,178	506,539	795,726	1,093,895	1,433,538	1,874,947
Shareholders' equity	280,369	294,621	368,694	431,178	506,539	795,726	1,093,895	1,433,538	1,874,947
Noncontrolling interests	-	-	-	-	-	-	-	-	-
Total assets	422,641	494,696	600,224	671,229	854,210	1,171,816	1,516,573	1,896,557	2,360,696
Net debt	-149,164	-85,984	-52,180	-31,559	-187,589	-339,966	-518,423	-747,552	-1,118,320
Cash and cash equivalents	149,164	116,582	85,537	106,702	262,544	339,966	518,423	747,552	1,118,320
Interest-bearing debt	0	30,598	33,357	75,143	74,955	0	0	0	0
Capital adequacy ratio	66%	60%	61%	64%	59%	68%	72%	76%	79%
<b>Summarized CF</b>									
CF from operating activities	67,830	78,889	70,224	32,668	285,971	335,182	498,988	646,486	755,458
Net income	69,787	87,301	130,400	62,290	161,177	375,353	575,700	705,000	769,100
Depreciation expense	11,756	14,968	21,396	26,104	27,075	25,612	27,700	31,900	37,300
Change in working capital	-2,774	-37,549	-70,736	-30,380	-2,648	-92,441	-104,412	-90,414	-50,942
Others	-10,939	14,169	-10,836	-25,346	100,367	26,658	0	0	0
CF from investing activities	-16,831	-46,907	-26,706	-27,940	-42,189	-34,552	-43,000	-52,000	-57,000
Expenditure on acquisition of fixed assets	-12,415	-17,158	-22,535	-19,592	-17,414	-33,012	-43,000	-52,000	-57,000
Others	-4,416	-29,749	-4,171	-8,348	-24,775	-1,540	0	0	0
CF from financial activities	-30,415	-68,736	-77,434	10,760	-82,818	-230,550	-277,531	-365,357	-327,691
Change in borrowings	0	28,468	32	39,998	0	-75,352	0	0	0
Purchase and sales of treasury stock	-14,028	-70,148	-50,042	-17	-50,080	-114,328	-234,000	-250,000	-200,000
Dividends paid to owner of parent co.	-15,594	-25,456	-25,418	-24,881	-27,320	-35,754	-43,531	-115,357	-127,691
Others	-793	-1,600	-2,006	-4,340	-5,418	-5,116	0	0	0
FCF	50,999	31,982	43,518	4,728	243,782	300,630	455,988	594,486	698,458

Source: Company reports and J.P. Morgan estimates.

Note: FCF above is calculated by Operating CF + Investing CF.

## Investment Thesis, Valuation and Risks

### **Advantest (6857)** (*Overweight; Price Target: ¥41,000*)

#### **Investment Thesis**

Growth in tester needs in connection with the lengthening of test times due to chip advances is a medium-term tailwind. We also expect a focus on Advantest's close ties with key customers in terms of the increasing performance of semiconductors brought about by generative AI advances. Another key factor is whether visibility on ROE upside can be improved through M&A and other capital allocation.

#### **Valuation**

Our December 2026 price target of ¥41,000 is based on our FY2027 EPS estimate and a P/E of around 42x, 1 standard deviation above the 10-year historical average of around 29x. We add a premium for Advantest due to our expectations for earnings growth.

#### **Risks to Rating and Price Target**

##### **Upside Scenario to Price Target/Rating**

- Increase in share of tester market
- More earnings opportunities as a result of M&A
- Growth in shareholder returns

##### **Downside Scenario to Price Target/Rating**

- Decline in share of tester market
- Inefficient capital allocation
- Slower growth in semiconductor capex market
- Deceleration in growth rate of test-time expansion
- Earnings growth moderating as demand shifts from new tester purchases to upgrades

## Advantest (6857): Summary of Financials

Income Statement						Cash Flow Statement					
	2025/3A	2026/3A	2027/3E	2028/3E	2029/3E		2025/3A	2026/3A	2027/3E	2028/3E	2029/3E
Revenue	779,707	1,128,610	1,577,500	1,906,500	2,103,500	Cash flow from operating activities	285,971	335,182	498,988	646,486	755,458
COGS	(334,622)	(402,503)	(534,500)	(648,800)	(713,200)	o/w Depreciation & amortization	27,075	25,612	27,700	31,900	37,300
Gross profit	445,085	726,107	1,043,000	1,257,700	1,390,300	o/w Changes in working capital	(2,648)	(92,441)	(104,412)	(90,414)	(50,942)
SG&A	(195,392)	(229,628)	(265,000)	(305,000)	(351,000)	Cash flow from investing activities	(42,189)	(34,552)	(43,000)	(52,000)	(57,000)
EBITDA	255,261	524,720	805,700	984,600	1,076,600	o/w Capital expenditure	(17,414)	(33,012)	(43,000)	(52,000)	(57,000)
D&A	(27,100)	(25,600)	(27,700)	(31,900)	(37,300)	as % of sales	2.2%	2.9%	2.7%	2.7%	2.7%
EBIT	228,161	499,120	778,000	952,700	1,039,300	Cash flow from financing activities	(82,818)	(230,550)	(277,531)	(365,357)	(327,691)
Net Interest	0	0	0	0	0	o/w Dividends paid	(27,320)	(35,754)	(43,531)	(115,357)	(127,691)
PBT	224,774	516,720	778,000	952,700	1,039,300	o/w Shares issued/(repurchased)	(50,080)	(114,328)	(234,000)	(250,000)	(200,000)
Tax	(63,597)	(141,367)	(202,300)	(247,700)	(270,200)	o/w Net debt issued/(repaid)	0	(75,352)	0	0	0
Minority Interest	-	-	-	-	-	Net change in cash	160,964	70,080	178,457	229,129	370,768
Net Income	161,177	375,353	575,700	705,000	769,100	Adj. Free cash flow to firm	268,557	302,170	455,988	594,486	698,458
Reported EPS	219.67	517.36	793.50	971.72	1,060.07	y/y Growth	1953.8%	12.5%	50.9%	30.4%	17.5%
DPS	39.00	59.00	119.00	146.00	212.00						
Payout ratio	17.8%	11.4%	15.0%	15.0%	20.0%						
Shares outstanding	766	732	732	732	732						
Balance Sheet						Ratio Analysis					
	2025/3A	2026/3A	2027/3E	2028/3E	2029/3E		2025/3A	2026/3A	2027/3E	2028/3E	2029/3E
Cash and cash equivalents	262,544	339,966	518,423	747,552	1,118,320	Gross margin	57.1%	64.3%	66.1%	66.0%	66.1%
Accounts receivable	113,031	228,731	303,741	368,695	405,291	EBITDA margin	32.7%	46.5%	51.1%	51.6%	51.2%
Inventories	209,707	231,718	307,708	373,509	410,584	EBIT margin	29.3%	44.2%	49.3%	50.0%	49.4%
Other current assets	337,209	496,441	647,441	778,196	851,867	Net profit margin	20.7%	33.3%	36.5%	37.0%	36.6%
Current assets	599,753	836,407	1,165,864	1,525,748	1,970,187	ROE	34.4%	57.6%	60.9%	55.8%	46.5%
PP&E	78,602	101,628	116,928	137,028	156,728	ROA	21.1%	37.1%	42.8%	41.3%	36.1%
LT investments	97,490	149,531	149,531	149,531	149,531	ROCE	30.1%	52.7%	60.9%	55.8%	46.5%
Other non current assets	97,490	149,531	149,531	149,531	149,531	SG&A/Sales	25.1%	20.3%	16.8%	16.0%	16.7%
Total assets	854,210	1,171,816	1,516,573	1,896,552	2,360,696	Net debt/Equity	NM	NM	NM	NM	NM
Short term borrowings	74,952	0	0	0	0	Net debt/EBITDA	NM	NM	NM	NM	NM
Payables	107,093	142,061	188,649	228,990	251,720	Sales/Assets (x)	1.0	1.1	1.2	1.1	1.0
Other short term liabilities	127,379	188,223	188,223	188,223	188,223	Assets/Equity (x)	1.6	1.6	1.4	1.4	1.3
Current liabilities	309,424	330,284	376,872	417,213	439,943	Interest cover (x)	-	-	-	-	-
Long-term debt	3	0	0	0	0	Operating leverage	297.8%	265.5%	140.5%	107.7%	88.0%
Other long term liabilities	38,247	45,806	45,806	45,806	45,806	Tax rate	28.3%	27.4%	26.0%	26.0%	26.0%
Total liabilities	347,671	376,090	422,678	463,019	485,749	Revenue y/y Growth	60.3%	44.7%	39.8%	20.9%	10.3%
Shareholders' equity	506,539	795,726	1,093,895	1,433,538	1,874,947	EBITDA y/y Growth	136.9%	105.6%	53.5%	22.2%	9.3%
Minority interests	0	0	0	0	0	EPS y/y growth	160.4%	135.5%	53.4%	22.5%	9.1%
Total liabilities & equity	854,210	1,171,816	1,516,573	1,896,552	2,360,696						
BVPS	690.37	1,096.77	1,507.75	1,975.89	2,584.30	Valuation					
y/y Growth	18.2%	58.9%	37.5%	31.0%	30.8%		2025/3A	2026/3A	2027/3E	2028/3E	2029/3E
Net debt/(cash)	(187,589)	(339,966)	(518,423)	(747,552)	(1,118,320)	P/E (x)	138.1	58.6	38.2	31.2	28.6
						P/BV (x)	43.9	27.7	20.1	15.4	11.7
						EV/EBITDA (x)	77.6	37.5	24.2	19.6	17.5
						Dividend Yield	0.1%	0.2%	0.4%	0.5%	0.7%

Source: Company data and J.P. Morgan estimates

Note: ¥ in millions (except per-share data). Fiscal year ends Mar. o/w - out of which

**Analyst Certification:** The Research Analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst’s personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report. For all Korea-based Research Analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that the Research Analyst’s analysis was made in good faith and that the views reflect the Research Analyst’s own opinion, without undue influence or intervention.

All authors named within this report are Research Analysts who produce independent research unless otherwise specified. In Europe, Sector Specialists (Sales and Trading) may be shown on this report as contacts but are not authors of the report or part of the Research Department.

**Important Disclosures**

- **Market Maker/ Liquidity Provider:** J.P. Morgan is a market maker and/or liquidity provider in the financial instruments of/related to Advantest (6857) or related entities.
- **Client:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients: Advantest (6857) or related entities.
- **Client/Non-Investment Banking, Securities-Related:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-investment-banking, securities-related: Advantest (6857) or related entities.
- **Client/Non-Securities-Related:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-securities-related: Advantest (6857) or related entities.
- **Potential Investment Banking Compensation:** J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Advantest (6857) or related entities.
- **Non-Investment Banking Compensation Received:** J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Advantest (6857) or related entities.
- **Debt Position:** J.P. Morgan may hold a position in the debt securities of Advantest (6857) or related entities, if any.

**Company-Specific Disclosures:** J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Important disclosures, including price charts and credit opinion history tables (if applicable), are available for compendium reports and all J.P. Morgan–covered companies, and certain non-covered companies, by visiting <https://www.jpmm.com/research/disclosures>, calling 1-800-477-0406, or e-mailing [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com) with your request.

Advantest (6857) (6857.T, 6857 JP) Price Chart



Date	Rating	Price (Y)	Price Target (Y)
27-Sep-23	N	4032	4,375
09-Feb-24	OW	6577	7,400
09-Jul-24	OW	6625	7,700
18-Oct-24	OW	8002	9,200
11-Dec-24	OW	8478	10,500
13-Jun-25	OW	8303	11,000
12-Sep-25	OW	13700	16,000
21-Jan-26	OW	21485	26,000
17-Mar-26	OW	24140	31,000
16-Jun-26	OW	29420	41,000

Source: Bloomberg Finance L.P. and J.P. Morgan; price data adjusted for stock splits and dividends. Initiated coverage Apr 26, 2001. All share prices are as of market close on the previous business day.

The chart(s) show J.P. Morgan’s continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period. J.P. Morgan ratings or designations: OW = Overweight, N= Neutral, UW = Underweight, NR = Not Rated

**Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:**

J.P. Morgan uses the following rating system: Overweight (over the duration of the price target indicated in this report, we expect this stock will outperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe); Neutral (over the duration of the price target indicated in this report, we expect this stock will perform in line with the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe); and Underweight (over the duration of the price target indicated in this report, we expect this stock will underperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe. NR is Not Rated. In this case, J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. Some stocks under coverage have a rating but no price target; in these cases, we expect the stock will outperform/perform in line/underperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe of the relevant duration of the region. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap Equity Research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those Research Analysts' coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying Research Analyst's coverage universe can be found on J.P. Morgan's Research website, <https://www.jpmorganmarkets.com>.

**Coverage Universe: Shikanai, Mio** : AGC (5201) (5201.T), Advantest (6857) (6857.T), Disco (6146) (6146.T), HOYA (7741) (7741.T), JX Advanced Metals (5016) (5016.T), KIOXIA Holdings (285A) (285A.T), Kaneka (4118) (4118.T), Lasertec (6920) (6920.T), Nikon (7731) (7731.T), Nippon Electric Glass (5214) (5214.T), Nippon Sheet Glass (5202) (5202.T), Nittobo (3110) (3110.T), Rigaku Holdings (268A) (268A.T), SCREEN Holdings (7735) (7735.T), Sumitomo Osaka Cement (5232) (5232.T), Taiheiyo Cement (5233) (5233.T), Tokyo Electron (8035) (8035.T), ULVAC (6728) (6728.T)

#### J.P. Morgan Equity Research Ratings Distribution, as of April 04, 2026

	Overweight (buy)	Neutral (hold)	Underweight (sell)
J.P. Morgan Global Equity Research Coverage*	51%	37%	12%
IB clients**	83%	79%	74%
JPMS Equity Research Coverage*	49%	39%	13%
IB clients**	94%	93%	85%

\*Please note that the percentages may not add to 100% because of rounding.

\*\*Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

**Equity Valuation and Risks:** For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <http://www.jpmorganmarkets.com>, contact the primary analyst or your J.P. Morgan representative, or email [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com). For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, <http://www.jpmorganmarkets.com>. This report also sets out within it the material underlying assumptions used.

#### History of Investment Recommendations:

A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of <http://www.jpmorganmarkets.com> where you can also search by analyst name, sector or financial instrument.

**Analysts' Compensation:** The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

**Registration of non-US Analysts:** Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US affiliates of J.P. Morgan Securities LLC, may not be registered as research analysts under FINRA rules, may not be associated persons of J.P. Morgan Securities LLC, and may not be subject to FINRA Rule 2241 or 2242 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

#### Other Disclosures

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

**UK MIFID FICC research unbundling exemption:** UK clients should refer to [UK MIFID Research Unbundling exemption](#) for details of J.P. Morgan's implementation of the FICC research exemption and guidance on relevant FICC research categorisation.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research

material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong Kong SAR (China); Taiwan (China); and Macau SAR (China).

J.P. Morgan Research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients should be aware of their own legal and compliance obligations when making investment decisions.

Any digital or crypto assets discussed in this research report are subject to a rapidly changing regulatory landscape. For relevant regulatory advisories on crypto assets, including bitcoin and ether, please see <https://www.jpmorgan.com/disclosures/cryptoasset-disclosure>.

The author(s) of this research report may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so.

**Exchange-Traded Funds (ETFs):** J.P. Morgan Securities LLC (“JPMS”) acts as authorized participant for substantially all U.S.-listed ETFs. To the extent that any ETFs are mentioned in this report, JPMS may earn commissions and transaction-based compensation in connection with the distribution of those ETF shares and may earn fees for performing other trade-related services, such as securities lending to short sellers of the ETF shares. JPMS may also perform services for the ETFs themselves, including acting as a broker or dealer to the ETFs. In addition, affiliates of JPMS may perform services for the ETFs, including trust, custodial, administration, lending, index calculation and/or maintenance and other services.

**Options and Futures related research:** If the information contained herein regards options- or futures-related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit <https://www.theocc.com/components/docs/riskstoc.pdf> for a copy of the Option Clearing Corporation’s Characteristics and Risks of Standardized Options or [https://www.finra.org/sites/default/files/2020-08/Security\\_Futures\\_Risk\\_Disclosure\\_Statement\\_2020.pdf](https://www.finra.org/sites/default/files/2020-08/Security_Futures_Risk_Disclosure_Statement_2020.pdf) for a copy of the Security Futures Risk Disclosure Statement.

**Changes to Interbank Offered Rates (IBORs) and other benchmark rates:** Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: [https://www.jpmorgan.com/global/disclosures/interbank\\_offered\\_rates](https://www.jpmorgan.com/global/disclosures/interbank_offered_rates)

**Notification for Credit Ratings:** If this material includes credit ratings, such credit ratings provided by Japan Credit Rating Agency, Ltd. (JCR) and Rating and Investment Information, Inc. (R&I), are credit ratings provided by Registered Credit Rating Agencies (credit rating agencies registered under the Financial Instruments and Exchange Law of Japan (FIEL)). With respect to credit ratings that are provided by credit rating agencies other than JCR and R&I and have no stipulation that such credit ratings are provided by Registered Credit Rating Agencies, this means that such credit ratings are Non Registered Ratings (credit ratings provided by credit rating agencies not registered under the FIEL). Among the Non Registered Ratings, with respect to those credit ratings provided by S&P Global Ratings (S&P), Moody’s Investors Service (Moody’s), or Fitch Ratings (Fitch), prior to making investment decision based on such Non Registered Ratings, please carefully read the “Explanation Letter regarding Non Registered Ratings” for the corresponding credit rating agency, which we separately have sent or will send.

**Private Bank Clients:** Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries (“J.P. Morgan Private Bank”), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including, but not limited to, the J.P. Morgan Corporate and Investment Bank and its Global Research division.

**Legal entity responsible for the production and distribution of research:** The legal entity identified below the name of the Reg AC Research Analyst who authored this material is the legal entity responsible for the production of this research. Where multiple Reg AC Research Analysts authored this material with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research. Where more than one legal entity is listed under an analyst’s name, the first legal entity is responsible for the production unless stated otherwise. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated below in the legal entity disclosures, this material has been distributed by the legal entity responsible for production, or where more than one legal entity is listed under the analyst’s name, the first legal entity will be responsible for distribution. If you have any queries, please contact the relevant Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.

**Legal Entities Disclosures and Country-/Region-Specific Disclosures:**

**Argentina:** JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina (“BCRA”- Central Bank of Argentina) and Comisión Nacional de Valores (“CNV”- Argentinian Securities Commission - ALYC y AN Integral N°51).

**Australia:** J.P. Morgan Securities Australia Limited (“JPMSAL”) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the Australian Securities and Investments Commission and is a Market Participant of ASX Limited, a Clearing and Settlement Participant of ASX Clear Pty Limited and a Clearing Participant of ASX Clear (Futures) Pty Limited. This material is issued and distributed in Australia by or on behalf of JPMSAL only to “wholesale clients” (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting <https://www.jpmm.com/research/disclosures>. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation

sizes. If applicable, in the course of conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been prepared in accordance with J.P. Morgan Australia's Research Independence Policy which can be found at the following link: [J.P. Morgan Australia - Research Independence Policy](#).

**Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Ombudsman J.P. Morgan: 0800-7700847 / 0800-7700810 (For Hearing Impaired) / [ouvidoria.jp.morgan@jpmchase.com](mailto:ouvidoria.jp.morgan@jpmchase.com).

**Canada:** J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Canadian Investment Regulatory Organization and the Ontario Securities Commission and is the participating member on Canadian exchanges. This material is distributed in Canada by or on behalf of J.P.Morgan Securities Canada Inc.

**Chile:** Inversiones J.P. Morgan Limitada is an unregulated entity incorporated in Chile.

**China:** J.P. Morgan Securities (China) Company Limited has been approved by CSRC to conduct the securities investment consultancy business.

**Colombia:** Banco J.P. Morgan Colombia S.A. is supervised by the Superintendencia Financiera de Colombia (SFC). Any reference in this material to products or services offered abroad by entities other than the Bank in Colombia is included exclusively for descriptive purposes. Such references do not constitute, and should not be construed as, promotional activity or the provision of financial products or services within Colombian territory, as defined under applicable Colombian regulation.

**Dubai International Financial Centre (DIFC):** JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - The Gate, West Wing, Level 3 and 9 PO Box 506551, Dubai, UAE. This material has been distributed by JP Morgan Chase Bank, N.A., Dubai Branch to persons regarded as professional clients or market counterparties as defined under the DFSA rules.

**European Economic Area (EEA):** Unless specified to the contrary, research is distributed in the EEA by J.P. Morgan SE ("JPM SE"), which is authorised as a credit institution by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB). JPM SE is a company headquartered in Frankfurt with registered address at TaunusTurm, Taunustor 1, Frankfurt am Main, 60310, Germany. The material has been distributed in the EEA to persons regarded as professional investors (or equivalent) pursuant to Art. 4 para. 1 no. 10 and Annex II of MiFID II and its respective implementation in their home jurisdictions ("EEA professional investors"). This material must not be acted on or relied on by persons who are not EEA professional investors. Any investment or investment activity to which this material relates is only available to EEA relevant persons and will be engaged in only with EEA relevant persons.

**Hong Kong:** J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong, and J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. JP Morgan Chase Bank, N.A., Hong Kong Branch (CE Number AAL996) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission, is organized under the laws of the United States with limited liability. Where the distribution of this material is a regulated activity in Hong Kong, the material is distributed in Hong Kong by or through J.P. Morgan Securities (Asia Pacific) Limited and/or J.P. Morgan Broking (Hong Kong) Limited.

**India:** J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai – 400098, is registered with the Securities and Exchange Board of India (SEBI) as a 'Research Analyst' having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number – INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: <http://www.jpmpi.com>. JPMorgan Chase Bank, N.A. - Mumbai Branch is licensed by the Reserve Bank of India (RBI) (Licence No. 53/ Licence No. BY.4/94; SEBI - IN/CUS/014/ CDSL : IN-DP-CDSL-444-2008/ IN-DP-NSDL-285-2008/ INBI00000984/ INE231311239) as a Scheduled Commercial Bank in India, which is its primary license allowing it to carry on Banking business in India and other activities, which a Bank branch in India are permitted to undertake. For non-local research material, this material is not distributed in India by J.P. Morgan India Private Limited. Compliance Officer: Ashutosh Sharma; [ashutosh.j.sharma@jpmchase.com](mailto:ashutosh.j.sharma@jpmchase.com); +912261575002. Grievance Officer: Ramprasadh K, [jpmpi.research.feedback@jpmorgan.com](mailto:jpmpi.research.feedback@jpmorgan.com); +912261573000. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Please visit [Terms and Conditions and Most Important Terms and Conditions \(MITC\)](#). The annual Compliance audit report is available at <http://www.jpmpi.com/#research>.

**Indonesia:** PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is registered and supervised by the Otoritas Jasa Keuangan (OJK).

**Korea:** J.P. Morgan Securities (Far East) Limited, Seoul Branch, is a member of the Korea Exchange (KRX). JPMorgan Chase Bank, N.A., Seoul Branch, is licensed as a branch office of foreign bank (JPMorgan Chase Bank, N.A.) in Korea. Both entities are regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). For non-macro research material, the material is distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch.

**Japan:** JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan.

**Malaysia:** This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X), which is a Participating Organization of Bursa Malaysia Berhad and holds a Capital Markets Services License issued by the Securities Commission in Malaysia.

**Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is member of the Mexican Stock Exchange (“Bolsa Mexicana de Valores”) and the Institutional Stock Exchange (“Bolsa Institucional de Valores”), and it is authorized to act as a broker dealer by the National Banking and Securities Exchange Commission (“Comisión Nacional Bancaria y de Valores”).

**New Zealand:** This material is issued and distributed by JPMSAL in New Zealand only to "wholesale clients" (as defined in the Financial Markets Conduct Act 2013). JPMSAL is registered as a Financial Service Provider under the Financial Service providers (Registration and Dispute Resolution) Act of 2008.

**Philippines:** J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission.

**Singapore:** This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMS) [MDDI (P) 057/08/2025 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited, and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore), both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of “accredited investors,” “expert investors” or “institutional investors,” as defined under Section 4A of the SFA. Recipients of this material in Singapore are to contact JPMS or JPMCB Singapore in respect of any matters arising from, or in connection with, the material.

**South Africa:** J.P. Morgan Equities South Africa Proprietary Limited and JPMorgan Chase Bank, N.A., Johannesburg Branch are members of the Johannesburg Securities Exchange and are regulated by the Financial Services Conduct Authority (FSCA).

**Taiwan:** J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. Material relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. **To the extent that J.P. Morgan Securities (Taiwan) Limited produces research materials on securities not listed on the Taiwan Stock Exchange or Taipei Exchange (“Non-Taiwan Listed Securities”), these materials shall not constitute securities recommendations for the purpose of applicable Taiwan regulations, and, for the avoidance of doubt, J.P. Morgan Securities (Taiwan) Limited does not act as broker for Non-Taiwan Listed Securities.** According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material that may give rise to conflicts of interests, unless otherwise disclosed in the “Important Disclosures” in this material.

**Thailand:** This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. The registered address is 548 One City Center Building, 50th Floor, Ploenchit Road, Lumpini, Pathum Wan, Bangkok 10330.

**UK:** Research is produced in the UK by J.P. Morgan Securities plc (“JPMS plc”) which is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority or J.P. Morgan Markets Limited (“JPML Ltd”) which is authorised and regulated by the Financial Conduct Authority. Unless specified to the contrary, this material is distributed in the UK by JPMS plc and is directed in the UK only to: (a) persons having professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) (Order) 2005 (“the FPO”); (b) persons outlined in article 49 of the FPO (high net worth companies, unincorporated associations or partnerships, the trustees of high value trusts, etc.); or (c) any persons to whom this communication may otherwise lawfully be made; all such persons being referred to as “UK relevant persons”. This material must not be acted on or relied on by persons who are not UK relevant persons. Any investment or investment activity to which this material relates is only available to UK relevant persons and will be engaged in only with UK relevant persons. A description of J.P. Morgan EMEA’s policy for prevention and avoidance of conflicts of interest related to the production of Research can be found at the following link: [J.P. Morgan EMEA - Research Independence Policy](#).

**U.S.:** J.P. Morgan Securities LLC (“JPMS”) is a member of the NYSE, FINRA, SIPC, and the NFA. JPMorgan Chase Bank, N.A. is a member of the FDIC. Material published by non-U.S. affiliates is distributed in the U.S. by JPMS who accepts responsibility for its content.

**General:** Additional information is available upon request. The information in this material has been obtained from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to J.P. Morgan and the Research Analyst’s involvement with the issuer that is the subject of the material. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. There may be certain discrepancies with data and/or limited content in this material as a result of calculations, adjustments, translations to different languages, and/or local regulatory restrictions, as applicable. These discrepancies should not impact the overall investment analysis, views and/or recommendations of the subject company(ies) that may be discussed in the material. Artificial intelligence tools may have been used in the preparation of this material, including assisting in data analysis, pattern recognition, and content drafting for research material. J.P. Morgan accepts no liability whatsoever for any loss

arising from any use of this material or its contents, and neither J.P. Morgan nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent J.P. Morgan's current opinions or judgment as of the date of the material only and are therefore subject to change without notice. Periodic updates may be provided on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. This material may include views on structured securities, options, futures and other derivatives. These are complex instruments, may involve a high degree of risk and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. The recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P. Morgan may trade as a principal on the basis of the Research Analysts' views and research, and it may also engage in transactions for its own account or for its clients' accounts in a manner inconsistent with the views taken in this material, and J.P. Morgan is under no obligation to ensure that such other communication is brought to the attention of any recipient of this material. Others within J.P. Morgan, including Strategists, Sales staff and other Research Analysts, may take views that are inconsistent with those taken in this material. Employees of J.P. Morgan not involved in the preparation of this material may have investments in the securities (or derivatives of such securities) mentioned in this material and may trade them in ways different from those discussed in this material. This material is not an advertisement for or marketing of any issuer, its products or services, or its securities in any jurisdiction.

**Confidentiality and Security Notice:** This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. This message is subject to electronic monitoring: <https://www.jpmorgan.com/disclosures/email>

**MSCI:** Certain information herein ("Information") is reproduced by permission of MSCI Inc., its affiliates and information providers ("MSCI") ©2026. No reproduction or dissemination of the Information is permitted without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES (INCLUDING MERCHANTABILITY OR FITNESS) AS TO THE INFORMATION AND DISCLAIMS ALL LIABILITY TO THE EXTENT PERMITTED BY LAW. No Information constitutes investment advice, except for any applicable Information from MSCI ESG Research. Subject also to [msci.com/disclaimer](https://www.msci.com/disclaimer)

**Sustainalytics:** Certain information, data, analyses and opinions contained herein are reproduced by permission of Sustainalytics and: (1) includes the proprietary information of Sustainalytics; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product or project; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Sustainalytics is not responsible for any trading decisions, damages or other losses related to it or its use. The use of the data is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>. ©2026 Sustainalytics. All Rights Reserved.

"Other Disclosures" last revised May 16, 2026.

---

**Copyright 2026 JPMorgan Chase & Co. All rights reserved. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. It is strictly prohibited to use or share without prior written consent from J.P. Morgan any research material received from J.P. Morgan or an authorized third-party ("J.P. Morgan Data") in any third-party artificial intelligence ("AI") systems or models when such J.P. Morgan Data is accessible by a third-party.**

Completed 16 Jun 2026 04:48 PM JST

Disseminated 16 Jun 2026 04:52 PM JST